Cytomegalovirus
Conditions
Keywords
cytomegalovirus, resistance, transplantation, Patient coming to an French transplantation center for solid organ or bone marrow transplant, with information and signed consent
Brief summary
The investigators aim is to determine the incidence of cytomegalovirus resistance to antivirals in a cohort study. The patients are included at their first CMV active infection and are followed during two years thereafter. When criteria for suspected resistance are meet, blood and urine samples are collected for virus isolation and further resistance phenotype, and for resistance genotype determination. Results are compared with baseline samples. Clinical information such as treatment, immunosuppressive regimen and clinical evolution will be collected. Through this study, the investigators aim to organize a national network for the detection and identification of CMV resistant strains that will be useful when new therapeutics will be available.
Interventions
BIOLOGICALdepistage
Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
Sponsors
University Hospital, Limoges
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Allogeneic bone marrow transplant recipient or solid organ transplant recipient, included in the cohort at the time of its firs active CMV infection (ie biological signs of CMV replication (viremia, ADN or ARN aemia, Antigenaemiapp65….) with or without fever, or clinical end organ disease symptoms
Exclusion criteria
* Patient without medical care.policy, * patient that did not signed the médical consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resistance incidence in our patients with subgroup analysis, by organ and by the use of prophylaxis or preemptive treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Strain diversity in baseline isolates and in resistant isolates Frequency of known resistance mutations Identification of new resistance-related mutations. | — |
Countries
France
Outcome results
None listed